Financhill
Buy
52

EXAS Quote, Financials, Valuation and Earnings

Last price:
$57.07
Seasonality move :
13.14%
Day range:
$56.01 - $57.38
52-week range:
$39.97 - $72.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.70x
P/B ratio:
4.45x
Volume:
2.7M
Avg. volume:
2.8M
1-year change:
5.59%
Market cap:
$10.7B
Revenue:
$2.8B
EPS (TTM):
-$5.51

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EXAS
Exact Sciences
$688.6M -$0.10 10.52% -84.17% $68.83
CTSO
CytoSorbents
$9M -$0.07 10.68% -41.38% $5.00
DCTH
Delcath Systems
$16.8M $0.03 179.13% -93.78% $23.17
GH
Guardant Health
$190M -$0.59 19.22% -35.86% $59.55
NTRA
Natera
$446.7M -$0.66 15.16% -106.89% $191.91
STRR
Star Equity Holdings
$16.4M -$0.25 18.67% -43.28% $8.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EXAS
Exact Sciences
$56.48 $68.83 $10.7B -- $0.00 0% 3.70x
CTSO
CytoSorbents
$0.85 $5.00 $53.2M -- $0.00 0% 1.35x
DCTH
Delcath Systems
$16.15 $23.17 $562.4M -- $0.00 0% 9.92x
GH
Guardant Health
$37.05 $59.55 $4.6B -- $0.00 0% 5.90x
NTRA
Natera
$152.48 $191.91 $20.8B -- $0.00 0% 10.68x
STRR
Star Equity Holdings
$2.06 $8.50 $6.6M 0.75x $0.00 0% 0.11x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EXAS
Exact Sciences
49.21% 0.148 28.45% 2.12x
CTSO
CytoSorbents
49.38% 1.160 22.69% 1.98x
DCTH
Delcath Systems
-- 2.997 -- 13.86x
GH
Guardant Health
128.98% 5.270 21.19% 3.61x
NTRA
Natera
6.09% 3.386 0.42% 3.58x
STRR
Star Equity Holdings
18.39% -0.314 40.47% 0.69x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EXAS
Exact Sciences
$500.5M -$89.8M -19.08% -35.57% -13.04% -$365K
CTSO
CytoSorbents
$6.2M -$3.9M -58.93% -106.57% -10.01% -$3.5M
DCTH
Delcath Systems
$16.9M $642K -37.34% -40.28% 3.25% $2.1M
GH
Guardant Health
$128.7M -$111M -39.31% -8518.58% -46.24% -$67.1M
NTRA
Natera
$316.8M -$79.2M -15.3% -19.19% -13.1% $22.6M
STRR
Star Equity Holdings
$3.1M -$2.8M -13.58% -15.99% -22.03% $200K

Exact Sciences vs. Competitors

  • Which has Higher Returns EXAS or CTSO?

    CytoSorbents has a net margin of -14.32% compared to Exact Sciences's net margin of -16.94%. Exact Sciences's return on equity of -35.57% beat CytoSorbents's return on equity of -106.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXAS
    Exact Sciences
    70.82% -$0.54 $4.7B
    CTSO
    CytoSorbents
    71.13% -$0.02 $28.7M
  • What do Analysts Say About EXAS or CTSO?

    Exact Sciences has a consensus price target of $68.83, signalling upside risk potential of 21.87%. On the other hand CytoSorbents has an analysts' consensus of $5.00 which suggests that it could grow by 488.93%. Given that CytoSorbents has higher upside potential than Exact Sciences, analysts believe CytoSorbents is more attractive than Exact Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    EXAS
    Exact Sciences
    18 4 0
    CTSO
    CytoSorbents
    1 1 0
  • Is EXAS or CTSO More Risky?

    Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison CytoSorbents has a beta of 1.171, suggesting its more volatile than the S&P 500 by 17.12%.

  • Which is a Better Dividend Stock EXAS or CTSO?

    Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. CytoSorbents pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXAS or CTSO?

    Exact Sciences quarterly revenues are $706.8M, which are larger than CytoSorbents quarterly revenues of $8.7M. Exact Sciences's net income of -$101.2M is lower than CytoSorbents's net income of -$1.5M. Notably, Exact Sciences's price-to-earnings ratio is -- while CytoSorbents's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.70x versus 1.35x for CytoSorbents. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXAS
    Exact Sciences
    3.70x -- $706.8M -$101.2M
    CTSO
    CytoSorbents
    1.35x -- $8.7M -$1.5M
  • Which has Higher Returns EXAS or DCTH?

    Delcath Systems has a net margin of -14.32% compared to Exact Sciences's net margin of 5.4%. Exact Sciences's return on equity of -35.57% beat Delcath Systems's return on equity of -40.28%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXAS
    Exact Sciences
    70.82% -$0.54 $4.7B
    DCTH
    Delcath Systems
    85.62% $0.03 $80.2M
  • What do Analysts Say About EXAS or DCTH?

    Exact Sciences has a consensus price target of $68.83, signalling upside risk potential of 21.87%. On the other hand Delcath Systems has an analysts' consensus of $23.17 which suggests that it could grow by 43.45%. Given that Delcath Systems has higher upside potential than Exact Sciences, analysts believe Delcath Systems is more attractive than Exact Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    EXAS
    Exact Sciences
    18 4 0
    DCTH
    Delcath Systems
    4 0 0
  • Is EXAS or DCTH More Risky?

    Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.805%.

  • Which is a Better Dividend Stock EXAS or DCTH?

    Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXAS or DCTH?

    Exact Sciences quarterly revenues are $706.8M, which are larger than Delcath Systems quarterly revenues of $19.8M. Exact Sciences's net income of -$101.2M is lower than Delcath Systems's net income of $1.1M. Notably, Exact Sciences's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.70x versus 9.92x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXAS
    Exact Sciences
    3.70x -- $706.8M -$101.2M
    DCTH
    Delcath Systems
    9.92x -- $19.8M $1.1M
  • Which has Higher Returns EXAS or GH?

    Guardant Health has a net margin of -14.32% compared to Exact Sciences's net margin of -46.77%. Exact Sciences's return on equity of -35.57% beat Guardant Health's return on equity of -8518.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXAS
    Exact Sciences
    70.82% -$0.54 $4.7B
    GH
    Guardant Health
    63.28% -$0.77 $865.6M
  • What do Analysts Say About EXAS or GH?

    Exact Sciences has a consensus price target of $68.83, signalling upside risk potential of 21.87%. On the other hand Guardant Health has an analysts' consensus of $59.55 which suggests that it could grow by 60.72%. Given that Guardant Health has higher upside potential than Exact Sciences, analysts believe Guardant Health is more attractive than Exact Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    EXAS
    Exact Sciences
    18 4 0
    GH
    Guardant Health
    15 3 0
  • Is EXAS or GH More Risky?

    Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Guardant Health has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.904%.

  • Which is a Better Dividend Stock EXAS or GH?

    Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXAS or GH?

    Exact Sciences quarterly revenues are $706.8M, which are larger than Guardant Health quarterly revenues of $203.5M. Exact Sciences's net income of -$101.2M is lower than Guardant Health's net income of -$95.2M. Notably, Exact Sciences's price-to-earnings ratio is -- while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.70x versus 5.90x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXAS
    Exact Sciences
    3.70x -- $706.8M -$101.2M
    GH
    Guardant Health
    5.90x -- $203.5M -$95.2M
  • Which has Higher Returns EXAS or NTRA?

    Natera has a net margin of -14.32% compared to Exact Sciences's net margin of -13.34%. Exact Sciences's return on equity of -35.57% beat Natera's return on equity of -19.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXAS
    Exact Sciences
    70.82% -$0.54 $4.7B
    NTRA
    Natera
    63.12% -$0.50 $1.3B
  • What do Analysts Say About EXAS or NTRA?

    Exact Sciences has a consensus price target of $68.83, signalling upside risk potential of 21.87%. On the other hand Natera has an analysts' consensus of $191.91 which suggests that it could grow by 25.86%. Given that Natera has higher upside potential than Exact Sciences, analysts believe Natera is more attractive than Exact Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    EXAS
    Exact Sciences
    18 4 0
    NTRA
    Natera
    12 0 0
  • Is EXAS or NTRA More Risky?

    Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Natera has a beta of 1.794, suggesting its more volatile than the S&P 500 by 79.445%.

  • Which is a Better Dividend Stock EXAS or NTRA?

    Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXAS or NTRA?

    Exact Sciences quarterly revenues are $706.8M, which are larger than Natera quarterly revenues of $501.8M. Exact Sciences's net income of -$101.2M is lower than Natera's net income of -$66.9M. Notably, Exact Sciences's price-to-earnings ratio is -- while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.70x versus 10.68x for Natera. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXAS
    Exact Sciences
    3.70x -- $706.8M -$101.2M
    NTRA
    Natera
    10.68x -- $501.8M -$66.9M
  • Which has Higher Returns EXAS or STRR?

    Star Equity Holdings has a net margin of -14.32% compared to Exact Sciences's net margin of -9.1%. Exact Sciences's return on equity of -35.57% beat Star Equity Holdings's return on equity of -15.99%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXAS
    Exact Sciences
    70.82% -$0.54 $4.7B
    STRR
    Star Equity Holdings
    24.27% -$0.52 $73.2M
  • What do Analysts Say About EXAS or STRR?

    Exact Sciences has a consensus price target of $68.83, signalling upside risk potential of 21.87%. On the other hand Star Equity Holdings has an analysts' consensus of $8.50 which suggests that it could grow by 312.62%. Given that Star Equity Holdings has higher upside potential than Exact Sciences, analysts believe Star Equity Holdings is more attractive than Exact Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    EXAS
    Exact Sciences
    18 4 0
    STRR
    Star Equity Holdings
    1 0 0
  • Is EXAS or STRR More Risky?

    Exact Sciences has a beta of 0.920, which suggesting that the stock is 7.968% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.871, suggesting its less volatile than the S&P 500 by 12.92%.

  • Which is a Better Dividend Stock EXAS or STRR?

    Exact Sciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exact Sciences pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

  • Which has Better Financial Ratios EXAS or STRR?

    Exact Sciences quarterly revenues are $706.8M, which are larger than Star Equity Holdings quarterly revenues of $12.9M. Exact Sciences's net income of -$101.2M is lower than Star Equity Holdings's net income of -$1.2M. Notably, Exact Sciences's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exact Sciences is 3.70x versus 0.11x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXAS
    Exact Sciences
    3.70x -- $706.8M -$101.2M
    STRR
    Star Equity Holdings
    0.11x 0.75x $12.9M -$1.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Cognizant Stock Be In 5 Years?
Where Will Cognizant Stock Be In 5 Years?

Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…

Why Did Forge Global Stock Go Down?
Why Did Forge Global Stock Go Down?

Shares of Forge Global (NYSE:FRGE), a platform that allows accredited…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
66
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
54
AAP alert for May 23

Advance Auto Parts [AAP] is down 0.98% over the past day.

Buy
67
IONQ alert for May 23

IonQ [IONQ] is down 0.48% over the past day.

Buy
75
URBN alert for May 23

Urban Outfitters [URBN] is down 1.24% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock